Biotechnology firm Mylab Discovery Solutions has entered into a partnership with US-based healthcare diagnostic device corporation known as Hemex Health to create transportable diagnostic options for the Point-of-Care (POC) testing of the novel coronavirus and other ailments.
The collaboration aims at augmenting testing capabilities for Covid-19 about the world. The organizations count on the initially solution from this technologies partnership to be launched by November 2021.
After the second wave, decentralised testing had come to be critical due to restricted capacity of standard laboratories. The transportable diagnostic device and tests assays allow testing at any place, in a wide variety of environmental circumstances and devoid of the want to transport the sample, enabling speedy outcome for the patients.
Mylab, backed by Adar Poonawalla of Serum Institute of India, is into diagnostics options like the country’s initially Covid-19 test kit and the self-test kits for Covid-19. Hasmukh Rawal, MD, Mylab Discovery Solutions, stated, “Hemex, had expertise in developing portable POC diagnostics machines which would be combined with Mylab’s fluorescence immunoassay (FIA) test kits to make testing available anywhere. The diagnostic solution will be jointly introduced in the international markets including the United States, Europe and Asia.”
Under the technologies partnership, Mylab would create test assays and Hemex would provide its Gazelle POC testing platform and experience. They will work on FIA and electrophoresis-based diagnostic tests which are more sensitive than the standard speedy antigen tests and have fewer false negatives, Mylab stated.
Patti White, CEO & Co-founder, Hemex Health, stated the partnership with Mylab would provide new breakthrough testing for Covid-19 and other ailments in the future. Hemex Health is backed by TiE Global Angels and Cleveland Clinic. It has distributed a point-of-care sickle cell test on their Gazelle diagnostic device in nine nations.